Health-related quality of life and estimates of utility in chronic kidney disease  by Gorodetskaya, Irina et al.
Kidney International, Vol. 68 (2005), pp. 2801–2808
Health-related quality of life and estimates of utility in chronic
kidney disease
IRINA GORODETSKAYA, STEFANOS ZENIOS, CHARLES E. MCCULLOCH, ALAN BOSTROM,
CHI-YUAN HSU, ANDREW B. BINDMAN, ALAN S. GO, and GLENN M. CHERTOW
Divisions of Nephrology and General Internal Medicine, Departments of Medicine, Epidemiology and Biostatistics, University of
California San Francisco, San Francisco, California; Graduate School of Business, Stanford University, Stanford, California; and
Division of Research, Kaiser Permanente of Northern California, Oakland, California
Health-related quality of life and estimates of utility in chronic
kidney disease.
Background. Health-related quality of life and estimates of
utility have been carefully evaluated in persons with end-stage
renal disease. Fewer studies have examined these parameters
in persons with chronic kidney disease (CKD).
Methods. To determine the relations among kidney func-
tion, health-related quality of life, and estimates of utility,
we administered the Kidney Disease Quality of Life Short
Form 36 (KDQOL-36TM), Health Utilities Index (HUI)-3, and
Time Trade-off (TTO) questionnaires to 205 persons with
CKD. Persons with CKD stages 4 and 5 (estimated GFR
<30 mL/min/1.73 m2, N = 115) were tested two to eight
times over the subsequent two years. The relations among esti-
mated glomerular filtration rate (eGFR), and changes in health-
related quality of life and utility over time were estimated using
mixed effect regression models. Models were adjusted for age,
sex, race, and diabetes.
Results. Mean scores on the KDQOL-36TM generic compo-
nents, HUI-3, and TTO suggested considerable loss of func-
tion and well-being in CKD relative to population norms. On
cross-sectional analysis, lower levels of kidney function were
associated with significantly lower scores on the SF-12 Physical
Health Composite (P = 0.002), the Burden of Kidney Disease
subscale (P < 0.0001), and the Effects of Kidney Disease sub-
scale (P < 0.0001) of the KDQOL-36TM. Kidney function was
significantly associated with the TTO (P = 0.008) and global
HUI-3 utility (P = 0.016) although these associations were at-
tenuated after adjustment for diabetes. A decline in eGFR was
associated with a significant increase in the reported Burden of
Kidney Disease (5.0 point change per year per mL/min/1.73 m2
decline in eGFR) and with marginally significant changes in the
Dexterity and Pain attributes of the HUI-3. Mean HUI-3 scores
for persons with CKD stages 4 and 5, absent dialysis, were in the
range previously reported for persons with stroke and severe
peripheral vascular disease.
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Conclusion. Health-related quality of life and estimates of
utility are distressingly low in persons with CKD. Self-reported
outcomes should be considered when evaluating health policy
decisions that affect this population.
End-stage renal disease (ESRD) affects over 400,000
adults in the United States, with the majority (>300,000)
of individuals requiring dialysis [1]. Mortality rates have
been in excess of 20% per year, hospitalizations are
more frequent, prolonged, and complicated, and the costs
of care are disproportionately higher than in the gen-
eral population. Moreover, several studies have demon-
strated that persons on dialysis experience significantly
reduced health-related quality of life (HRQOL) [2–6].
More recently, attention has focused on the much
larger population of persons with chronic kidney dis-
ease (CKD) who do not require dialysis. Based on
estimates from the National Health and Nutrition Eval-
uation Survey (NHANES) III [7], more than 10% of
the adult U.S. population has some degree of CKD, de-
fined as an estimated glomerular filtration rate (eGFR)
below 60 mL/min/1.73 m2 with or without proteinuria,
or proteinuria with lesser reductions in eGFR (60–
89 mL/min/1.73 m2). Epidemiologic studies have sug-
gested that CKD is associated with a several-fold increase
in mortality and considerable morbidity, particularly
complications of cardiovascular disease [8, 9]. For exam-
ple, we recently demonstrated 1.2-, 1.8-, 3.2-, and 5.9-fold
increases in the risk of death associated with eGFR 45 to
59, 30 to 44, 15 to 29, and <15 mL/min/1.73 m2 [9]. To
date, relatively few studies have examined HRQOL or
utility in persons with CKD. Understanding issues from
the patients’ perspective, such as the burden experienced
in association with kidney disease, could help to guide
physicians in designing interventions to reduce mortal-
ity and morbidity and improve HRQOL associated with
CKD.
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In the context of developing decision models for al-
ternative management strategies in CKD and ESRD,
we obtained several questionnaires from persons within
two ethnically and socioeconomically diverse University-
affiliated ambulatory Nephrology practices and one
University-affiliated dialysis unit. We aimed to capture
a broad cross-section of persons with varying severity of
CKD, and to examine changes in HRQOL and utility
over time. We hypothesized that these parameters would
be related to the severity of CKD, and would decline in
concert with declining eGFR.
METHODS
Study subjects and procedures
Study subjects were pooled from two studies incor-
porating the same battery of instruments and led by
the same research team. The first was a cross-sectional
pilot project in preparation for participation in the
Chronic Renal Insufficiency Cohort (CRIC) study [10],
and included individuals with eGFR between 30 and
70 mL/min/1.73 m2. The second was a longitudinal study
exploring self-reported outcomes among individuals with
eGFR <30 mL/min/1.73 m2. For the latter study, ques-
tionnaires were administered quarterly (± 45 days), and
attempts were made to continue questionnaire adminis-
tration after the initiation of dialysis. At each visit, sub-
jects were asked to report on any changes in health status
(e.g., new or exacerbated health conditions), as well as
interim hospitalization and emergency department visits.
Recruitment began in May 2002; the last follow-up visit
was conducted in June 2004. All subjects were English-
speaking and signed a written informed consent. The
UCSF Committee on Human Research approved the
study protocol and associated documents.
For subjects followed longitudinally, the question-
naires were administered on the day of a scheduled of-
fice visit, usually before the visit was completed. For
hemodialysis patients, study interviews were conducted
during the hemodialysis session. The TTO was performed
as a structured interview, using a standard script. Each
subject was asked to compare (“trade-off”) five years
of life in current health with × (ranging from 1 day to
4 years 11 months) years of life in his or her perfect state
of health. Using a series of questions bracketing the initial
responses, a single utility indicator was derived, typically
between 0 (death) and 1 (perfect health).
The Kidney Disease Quality of Life Short Form 36
(KDQOL-36TM) self-report questionnaire was originally
developed for individuals with ESRD. The KDQOL-
36TM consists of the SF-12 Physical Health and Mental
Health Composite scores along with the Burden of Kid-
ney Disease and Effects of Kidney Disease subscales [12].
All measures were scored on a 0 to 100 point scale with
higher values representing better HRQOL. We used the
“acute” form of the SF-12 used in KDQOL-36TM ques-
tionnaire (i.e., an item on general health refers to current
health, with all of the remaining questions focusing on
the patient’s underlying health status during the preced-
ing four weeks).
The Health Utilities Index (HUI) is a 17-item self-
administrated questionnaire based on multi-attribute
utility theory. The HUI health status classification system
was developed by Feeny et al [13] to address capacity
on eight key attributes: vision, hearing, speech, ambu-
lation, dexterity, emotion, cognition (including memory
and thinking), and pain. The HUI-3 defines a preference
or utility function that can be used to calculate the de-
sirability of, or preference for, alternative health states.
For each attribute there are five or six levels, ranging
from normal to severely impaired. The version of HUI-3
that we used in these studies was designed to elicit re-
sponses from a wide variety of subjects about their health
during the four weeks before the survey. The HUI-3
single-attribute utility scales are defined for the interval 1
(perfect health) to 0 (most disabled). The HUI-3 multi-
attribute utility scale is defined for the interval −0.36
to 1.00. One represents perfect health, zero represents
death, while negative scores represent states considered
worse than death.
Covariates
We collected data on age, sex, self-reported race or
ethnicity, socioeconomic status, comorbid conditions, se-
lect medications, and relevant laboratory results from pa-
per and electronic medical records. A modified Charlson
Comorbidity Index (CCI) was employed as a summary
measure of comorbidity [14]. To the original index we
added arrhythmia and morbid obesity; we also halved
the Charlson weight of HIV/AIDS. The modified CCI
scores ranged from 0 to 19, with higher scores indicating
more severe comorbidity. The eGFR was calculated using
the abbreviated (4-variable) MDRD equation with cal-
ibrated serum creatinine concentrations [15]. Estimated
GFR was categorized using the National Kidney Founda-
tion CKD staging system [16]. We collected data prospec-
tively on hospitalization, emergency department visits,
and self-reported changes in health status. No efforts
were made to determine specific reasons for hospital-
ization, including whether hospitalization was related to
progressive CKD.
To evaluate the extent of recruitment bias, we com-
pared baseline characteristics of study subjects with
individuals who were approached but had refused to
participate.
Statistical analysis
Descriptive statistics were calculated and reported as
mean ± standard deviation (or median with interquartile
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Table 1. Demographic and clinical characteristics of the study cohort
GFR ≥60 30≤GFR<60 15≤GFR<30 GFR <15, ND GFR <15 + dialysis Dialysis P value
(N = 22) (N = 51) (N = 66) (N = 28) (N = 66) (N = 38) ND (+D)
Age years 63.2 ± 10.3 61.4 ± 10.4 65.6 ± 14.0 65.8 ± 14.6 60.9 ± 16.2 57.3 ± 16.5 0.086 (0.88)
Female % 59% 59% 44% 61% 46% 34% 0.53 (0.11)
Race %
Caucasian 71% 64% 53% 52% 40% 31%
African American 5% 14% 23% 33% 32% 31%
Asian and other 24% 22% 24% 15% 27% 37% 0.024 (0.003)
Modified CCI score 2.9 ± 2.0 3.4 ± 2.1 4.3 ± 2.5 4.9 ± 2.5 3.0 ± 2.7 1.6 ± 1.8 0.0003 (0.55)
Diabetes mellitus % 18% 43% 44% 68% 52% 40% 0.003 (0.028)
Congestive heart disease % 5% 12% 42% 36% 26% 18% <0.0001 (0.015)
Ischemic heart disease % 9% 12% 38% 21% 15% 11% 0.014 (0.42)
Peripheral vascular disease % 5% 6% 5% 7% 5% 3% 0.85 (0.83)
Musculoskeletal disease % 55% 53% 74% 71% 35% 8% 0.022 (0.045)
Respiratory disease % 23% 14% 27% 36% 20% 8% 0.055 (0.71)
Gastrointestinal disease % 27% 39% 53% 54% 27% 8% 0.022 (0.49)
Neurological disease % 14% 37% 33% 43% 21% 5% 0.13 (0.46)
Psychiatric disease % 41% 14% 8% 18% 8% 0% 0.039 (0.002)
Genitourinary disease % 23% 20% 36% 32% 17% 5% 0.10 (0.65)
Hematologic disease % 18% 28% 64% 89% 59% 37% <0.0001 (<0.0001)
Lipid disorders % 36% 59% 55% 82% 39% 8% 0.011 (0.27)
Obesity % 18% 29% 21% 21% 9% 0% 0.70 (0.023)
Liver disease % 9% 4% 11% 7% 5% 3% 0.62 (0.77)
Cancer % 23% 18% 15% 21% 14% 8% 0.85 (0.33)
HIV % 0% 0% 1.5% 1.5% 3% 3% 0.15 (0.15)
Organ transplant % 0% 6% 1.5% 11% 5% 0% 0.30 (0.75)
Serum albumin g/dL n/a 3.7 ± 0.4 3.6 ± 0.5 3.6 ± 0.5 3.8 ± 0.6 3.9 ± 0.5 0.24 (0.095)
Hemoglobin g/dL n/a 11.7 ± 1.3 12.9 ± 1.9 10.8 ± 1.3 11.4 ± 1.3 11.8 ± 1.1 0.004 (0.036)
Abbreviations are: CCI, modified Charlson Comorbidity Index; GFR, glomerular filtration rate, estimated by abbreviated MDRD equation; hematologic disease
includes anemia. P value refers to chi-square (trend) test or Spearman correlation coefficients across categories. ND refers to the test excluding persons on dialysis (N
= 28 in CKD stage 5); +D refers to the test including persons on dialysis (N = 66 in CKD stage 5).
range) or proportions. Adjusted mean scores on ques-
tionnaires were calculated using general linear mod-
els and compared with analysis of variance. Highly
skewed variables were compared using the Kruskal-
Wallis test. Trends across categories were analyzed using
the Spearman (rank-based) correlation coefficient. Anal-
yses were adjusted for age, sex, race or ethnicity, and di-
abetes mellitus. To capture the potential contribution of
comorbidity unrelated to diabetes, we performed addi-
tional analyses adjusting for the modified CCI. We com-
pared questionnaire results across categories of eGFR,
with the hemodialysis patients included and excluded
from the <15 mL/min/1.73 m2 group.
We evaluated the change in the HRQOL and util-
ity over time using mixed effect regression models, with
eGFR incorporated as a time-varying covariate. Mixed
effect models accommodate the correlated nature of the
longitudinal data and allow for incorporation of all avail-
able data, without restriction on the number of observa-
tions per subject or differential timing of observations. All
longitudinal data were adjusted for the effects of age, sex,
race or ethnicity, and diabetes. We also modeled hospital-
ization, emergency department visits, and self-reported
changes in health status as time-varying covariates.
Due to the exploratory nature of the analysis, we did
not perform formal adjustment for multiple comparisons.
We considered P values < 0.01 as statistically significant
and P values between 0.01 and 0.05 of marginal signif-
icance. Analyses were conducted using SAS version 8.2
(SAS Institute, Cary, NC, USA).
RESULTS
The demographic and baseline clinical characteristics
of the study sample are shown in Table 1. Overall, the
mean age was 62.8 ± 12.7 years, 52% were female, 54%
white, 22% African American, and 22% Asian-Pacific Is-
lander. The majority of subjects (55%) earned <$2,000
per month, 27% lived alone, and 18% were widowed. The
mean age was not different across CKD stage, nor was
the proportion of women. Persons with stage 5 CKD were
more likely to be African American and less likely to be
white. There were no significant differences in income, ed-
ucation, marital or living status by CKD stage. Excluding
individuals on dialysis, subjects with lower eGFR (stage 4
and 5 CKD) had more comorbid disease than those with
higher eGFR. As a summary measure, there was a step-
wise increase in the mean modified CCI score—2.9, 3.4,
4.3, and 4.9 for patients with CKD stages 2, 3, 4, and 5,
respectively (P = 0.0003).
We compared subjects who responded with those sub-
jects who refused participation. Potential subjects who
refused were significantly older (67.8 vs. 62.8 years, P =
0.035), more likely to be Asian-Pacific Islander (40% vs.
22%, P < 0.001), and had more comorbidity (4.8 vs. 3.5
on modified CCI, P = 0.0015).
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Table 2. Health-related quality of life and utility by eGFR
GFR ≥60 30 ≤GFR<60 15 ≤GFR<30 GFR <15, ND GFR<15 + dialysis Dialysis P value
(N = 22) (N = 50) (N = 65) (N = 28) (N = 66) (N = 38) ND (+D)
Burden of Kidney Disease 85.9 ± 19.4 85.4 ± 19.8 74.9 ± 26.4 63.4 ± 23.4 49.3 ± 26.5 38.6 ± 23.8 <0.0001 (<0.0001)
Effects of Kidney Disease 92.4 ± 14.3 91.6 ± 11.1 87.5 ± 16.3 80.4 ± 15.8 70.4 ± 20.2 62.7 ± 20.1 0.0002 (<0.0001)
SF-12 Physical Composite 45.9 ± 13.4 43.6 ± 11.8 37.1 ± 12.6 35.4 ± 11.1 36.9 ± 9.9 38.0 ± 8.8 0.0001 (0.0002)
SF-12 Mental Composite 50.7 ± 6.8 50.4 ± 10.3 52.9 ± 10.9 48.4 ± 11.3 49.3 ± 9.9 50.0 ± 9.0 0.20 (0.16)
Time Trade-Off 0.90 ± 0.17 0.87 ± 0.24 0.85 ± 0.23 0.85 ± 0.24 0.77 ± 0.32 0.72 ± 0.37 0.09 (0.008)
HUI-3 Global Utility 0.67 ± 0.31 0.67 ± 0.31 0.55 ± 0.34 0.54 ± 0.36 0.54 ± 0.33 0.54 ± 0.31 0.04 (0.016)
Single attributes
Ambulation 0.90 ± 0.23 0.91 ± 0.16 0.82 ± 0.23 0.75 ± 0.27 0.77 ± 0.29 0.78 ± 0.30 0.0002 (0.001)
Cognition 0.89 ± 0.16 0.89 ± 0.20 0.87 ± 0.22 0.90 ± 0.16 0.92 ± 0.12 0.93 ± 0.09 0.99 (0.89)
Dexterity 0.96 ± 0.12 0.98 ± 0.05 0.93 ± 0.20 0.84 ± 0.33 0.91 ± 0.24 0.94 ± 0.16 0.13 (0.22)
Emotion 0.93 ± 0.14 0.91 ± 0.13 0.94 ± 0.09 0.91 ± 0.11 0.90 ± 0.16 0.89 ± 0.19 0.60 (0.41)
Hearing 0.96 ± 0.15 0.91 ± 0.25 0.88 ± 0.27 0.96 ± 0.15 0.94 ± 0.20 0.92 ± 0.22 0.38 (0.39)
Pain 0.78 ± 0.29 0.87 ± 0.18 0.77 ± 0.28 0.76 ± 0.26 0.76 ± 0.26 0.76 ± 0.27 0.26 (0.14)
Speech 0.98 ± 0.05 0.99 ± 0.06 0.97 ± 0.11 0.96 ± 0.10 0.96 ± 0.10 0.96 ± 0.10 0.22 (0.08)
Vision 0.94 ± 0.08 0.90 ± 0.17 0.87 ± 0.26 0.85 ± 0.20 0.86 ± 0.23 0.86 ± 0.25 0.38 (0.63)
P value refers to Spearman correlation coefficients across categories. ND refers to the test excluding persons on dialysis (N = 28 in CKD stage 5); +D refers to the
test including persons on dialysis (N = 66 in CKD stage 5).
Cross-sectional analyses
Estimated GFR and serum creatinine concentrations.
The median eGFR at baseline was 28.0 mL/min/1.73 m2
(interquartile range 20.4 to 51.8 mL/min/1.73 m2). The
median serum creatinine concentrations were 2.0 mg/dL
(1.1–2.8 mg/dL) in women and 2.6 mg/dL (1.6–3.2 mg/dL)
in men.
Instruments. The Effects of Kidney Disease and
Burden of Kidney Disease subscales were most tightly
correlated (r = 0.65). The Physical Health Composite was
directly correlated with the global HUI-3 score (r = 0.58),
especially the ambulation (r = 0.58), pain (r = 0.56) and
dexterity (r = 0.32) attributes. The Mental Health Com-
posite was less strongly correlated with the global HUI-3
score (r = 0.34), and correlated with the attributes of
emotion (r = 0.59) and cognition (r = 0.36). The TTO
and HUI-3, despite jointly used to capture utility, were
not correlated (r = 0.03).
In general, higher scores (better health) on the
KDQOL-36TM scales, TTO, and HUI-3 were observed
among individuals who were married (compared with
single or widowed) with higher education and income
status. The Physical Health Composite scores tended to
be higher among individuals with higher concentrations
of serum albumin (r = 0.24) and hemoglobin (r = 0.24).
HUI-3 scores were also directly correlated with serum
albumin concentrations (r = 0.23).
Health-related quality of life and utility by CKD stage.
There were significant differences by CKD stage in all
instruments tested, except for the Mental Health Com-
posite score (Table 2). The Burden of Kidney Disease and
Effects of Kidney Disease subscales declined monoton-
ically with lower eGFR, perhaps reflecting the intended
specificity of these questions for CKD. Among the sub-
jects with CKD stage 5, the Burden and Effects were
much more pronounced among those requiring dialysis.
The relations among the generic instruments and eGFR
were nonlinear, and seemed to reflect a breakpoint at
CKD stage 4 (eGFR <30 mL/min/1.73 m2). For example,
the Physical Health Composite score was approximately
seven points lower among subjects with eGFR <30, com-
pared with those whose eGFR was ≥30 mL/min/1.73 m2
(P = 0.0005). The mean HUI-3 score was also significantly
lower among subjects with eGFR <30 (0.55 vs. 0.67, P =
0.03). Of the eight HUI-3 attributes, only the ambula-
tion attribute was significantly lower (P = 0.001) among
subjects with lower eGFR. The results were essentially
unchanged with adjustment for age, sex and race, or eth-
nicity. The mean HUI-3 scores were strongly associated
with diabetes (mean HUI-3 0.47 ± 0.35 vs. 0.69 ± 0.26,
P < 0.0001). After adjustment for diabetes, the difference
in mean HUI-3 by eGFR category was no longer statis-
tically significant (P = 0.21). In contrast, the differences
in the Burden of Kidney Disease and Effects of Kidney
Disease subscales and the Physical Health Composite by
eGFR category remained statistically significant after ad-
justment for age, sex, race or ethnicity, and diabetes. Re-
sults were nearly identical when the modified CCI was
used instead of diabetes in adjusted analyses.
Longitudinal analyses
One hundred and fifteen subjects with eGFR <30 mL/
min/1.73 m2 (corresponding to columns 4–7 on Table 1)
were evaluated at least twice. The mean number of vis-
its per subject was 3.3 (range 2–8), corresponding to
an average length of follow-up of 10 months (range
6–24 months). Seventeen (15%) subjects were lost to
follow-up because dialysis was initiated at non–UCSF-
affiliated dialysis units; 11 (10%) subjects were withdrawn
due to death or transplantation, or other health prob-
lems (e.g., repeated hospitalization) precluding contin-
ued participation.
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The overall mean rate of change in eGFR was esti-
mated at −1.3 (−2.4 to −0.4) mL/min/1.73 m2/year (P =
0.04). The rate of change in eGFR was unrelated to age
(P = 0.18), sex (P = 0.73), or diabetes (P = 0.31) in this
cohort. However, the decline in eGFR was significantly
steeper for African Americans (P = 0.0002) and Asian-
Pacific Islanders (P = 0.04) compared with whites. Over-
all changes in HRQOL and utility were found only for
three single attributes of the HUI-3: ambulation (P =
0.01), cognition (P = 0.03), and dexterity (P = 0.017).
There were no significant changes over time in the TTO,
Effects or Burden of Kidney Disease, or the Physical
Health and Mental Health Composite Scores. However,
we observed a significant relation between the change in
eGFR and change in the Burden of Kidney Disease score
(5.0 point change per year per mL/min/1.73 m2 decline in
eGFR, P = 0.006). In other words, while the study sam-
ple reported no overall change in the Burden of Kidney
Disease, those who experienced increased burden were
those who also experienced a decline in eGFR. The global
HUI-3 declined by 0.039 per year per mL/min/1.73 m2
decline in eGFR, a change that did not reach statistical
significance (P = 0.08). There were relations of marginal
significance among the change in eGFR and the HUI-3
attributes of dexterity (P = 0.024) and pain (P = 0.048).
Temporal changes in HRQOL and utility were unrelated
to age, sex, race or ethnicity, and diabetes.
Effects of changes in health status and initiation
of dialysis
Hospitalization, emergency department visits, and self-
reported changes in health status were associated with
changes in HRQOL and utility. For example, hospitaliza-
tion was associated with significant declines in the Phys-
ical Health Composite score (mean decrease 2.72, 95%
CI 0.88 to 4.58), the Burden of Kidney Disease subscale
(mean decrease 6.51, 95% CI 2.15 to 10.9), and the global
HUI-3 score (mean decrease 0.06, 95% CI 0.01 to 0.12).
Emergency department visits were associated with sig-
nificant declines in the Mental Health Composite score
(mean decrease 3.17, 95% CI 0.95 to 5.40) and the Bur-
den of Kidney Disease (mean decrease 7.10, 95% CI
2.52 to 11.7), and with nonsignificant declines in Physical
Health Composite and HUI-3. Self-reported changes in
health status were associated with significant declines in
the global HUI-3 score (mean decrease 0.09, 95% CI 0.04
to 0.14) as well as significant declines in the ambulation,
cognition, dexterity, emotion, and pain attributes. Self-
reported changes in health status were also associated
with significant declines in Physical and Mental Health
Composite scores.
Thirty-one (27%) subjects initiated dialysis during the
two-year period, although only 14 (12%) remained at
the University-affiliated dialysis unit because of space
constraints. Among those who transitioned within CKD
stage 5 (from nondialysis to dialysis-requiring CKD),
there were significant decreases in the Burden (P = 0.007)
and Effects of Kidney Disease (P = 0.002) scores (i.e.,
more burden and more pronounced effects of kidney
disease), as expected. There were no statistically signif-
icant changes in the Physical Health or Mental Health
Composite scores, TTO, or HUI-3 with dialysis initiation,
relative to subjects who remained dialysis independent.
Among HUI-3 attributes, only ambulation declined sig-
nificantly upon initiation of dialysis (P = 0.01). There was
no significant deterioration of HRQOL or estimated util-
ity for subjects once established on dialysis.
DISCUSSION
In this study, we demonstrated significant associations
among estimated glomerular filtration rate (eGFR) and
self-reported physical function by the KDQOL-36TM
Physical Health Composite score, the Effects and Bur-
den of Kidney Disease (also from the KDQOL-36TM),
and estimated utility, as measured by the time trade-off
(TTO) and Health Utilities Index-3 (HUI-3). Except for
the TTO, which demonstrated a roughly linear associa-
tion with eGFR, most parameters of HRQOL and util-
ity showed a drop-off at CKD stage 4 or eGFR <30 mL/
min/1.73 m2. Over time, a decline in eGFR was associated
with an increase in the self-reported burden of kidney dis-
ease. Changes in health status contributed significantly to
declines in HRQOL and estimates of utility.
Relatively few studies have evaluated HRQOL or
functional status in CKD. Chow et al found lower self-
reported physical function in persons with a creati-
nine clearance <60 mL/min/1.73 m2, independent of
age, sex, and other confounding factors [17]. Using
data from the African American Study of Kidney Dis-
ease and Hypertension (AASK Study), Kusek et al [18]
showed a direct correlation between self-reported phys-
ical function and 125−iothalamate GFR. Other measures
of functional status, such as the Karnofsky scale and phys-
ical activity–related symptoms, have also been associated
with CKD [19, 20]. Among participants in Heart and Es-
trogen/Progestin Replacement Study, Kurella et al [21]
showed that eGFR was associated with lower baseline
scores on the Duke Activity Status Index (a physical
activity questionnaire), and when followed over time,
women with a decrease in eGFR had a steeper decline
in self-reported physical activity.
The overall questionnaire scores for subjects with
CKD, excluding those on dialysis, were distressingly
low. The healthy adult population scores a mean of ap-
proximately 50 on the Physical Health Composite scale.
According to Blanchard et al [22], a Physical Health Com-
posite score below 43 suggests that individuals perceive
physical health problems that impede life functioning;
2806 Gorodetskaya et al: Health-related quality of life and utility estimates in CKD
Alzheimer's disease
Stroke
GFR <30 mL/min/1.73 m2
Metastatic colorectal cancer 
Intermittent claudication
GFR 30-60 mL/min/1.73 m2
Arthritis
Brain cancer
Hepatitis
Colorectal cancer
Coronary heart disease
Gastrointestinal disorder
Diabetes mellitus
Respiratory disease
General adult population
0.22
0.54
0.54
0.65
0.66
0.67
0.77
0.78
0.84
0.85
0.87
0.89
0.90
0.93
0.93
0 0.2 0.4 0.6 0.8 1
Health utility index
Fig. 1. HUI-3 Scores in published reports of chronic diseases. Shaded bars from current study included. Nonshaded bars from references summarized
in [13, 26–31].
mean scores for subjects with CKD stages 4 and 5 were
well below this threshold. Compared with recently pub-
lished reports, subjects with CKD stages 4 and 5 exhibited
lower levels of physical function than persons affected by
hypertension, diabetes mellitus, asthma, chronic obstruc-
tive lung disease, and liver failure, whose scores on the
Physical Health Composite ranged from 39 to 46 [23–25].
The HUI-3 scores were also low relative to other dis-
ease states. Health Utilities Index-3 scores for the general
adult population have been reported in the 0.90 to 0.94
[13, 26]. Figure 1 shows HUI-3 scores from a broad range
of populations with chronic disease. Persons with CKD
stage 3 and CKD stages 4 and 5 are included for compar-
ison; only persons with stroke and Alzheimer’s disease
reported the same or lower utility [27–31].
Estimates of utility are typically used in economic anal-
yses, such as those comparing cost-effectiveness of com-
peting strategies, and in resource allocation decisions. The
classic tool originally used in utility assessment was the
standard gamble [32]; the TTO was developed later and
has been thought to be more intuitive. The weights used
in the calculation of HUI-3 scores were developed us-
ing both standard gamble and TTO instruments. Both
the standard gamble and TTO have their foundations
in expected utility theory but some of their critics argue
that this theory has not been verified in clinical practice.
Notably, these techniques have the ability to reflect indi-
vidual preferences about risk, but it is argued that such
considerations may not be relevant when resource allo-
cation decisions are being made [33–35].
Our results show that utility estimates derived by the
different techniques considered here are not compara-
ble. Using a global HUI-3 score of 0.94 to represent good
health, a quality-adjusted life year (QALY) for subjects
with CKD stages 4 and 5 would be 0.58 (0.54 divided
by 0.94), in contrast to the 0.85 and 0.72 QALY derived
from TTO for CKD stages 4 and 5, respectively. These
differences may be attributed to several factors, such as
differences in the sensitivity of these instruments to spe-
cific domains affected by CKD or to risk taking. The
instruments differ in that the HUI-3 is focused on phys-
ical health attributes, where TTO integrates functional
capacity, disease burden, and risk tolerance, the latter
having particular relevance among persons with appre-
hension about CKD progression and potentially starting
dialysis. Since the association between TTO and eGFR
was roughly linear, where the association between eGFR
and HUI-3 appeared to abruptly drop at CKD stage 4,
it is possible that specific social or physical functions or
risk preferences that are affected by the stage of CKD
may not captured by the HUI-3. Conversely, Arnesen
and Trommald [36] argued against the use of TTO for
quality adjustment, using as an example the widely vari-
able estimates of QALY in hemodialysis patients derived
from multiple reports. Thus, when considering applica-
tion of utility estimates into cost-effectiveness analysis, a
reasonable strategy would be to use results from both in-
struments as brackets for sensitivity analyses [33, 35–37].
This study has several strengths. The population was di-
verse, the sample size relatively large, and multiple tests
of HRQOL and utility were obtained. In addition to ex-
tensive cross-sectional analyses, we had serial data on a
relatively large number of subjects with advanced CKD,
many of whom experienced adverse health events or ini-
tiation of dialysis. As such, we were able to compare and
contrast results on multiple studies, and evaluate the face
validity of scores in response to major life events.
The study has several important limitations. While
study subjects were broadly representative of the CKD
population in terms of age, sex, race or ethnicity, and other
clinical characteristics, all subjects were derived at a sin-
gle institution (limiting generalizability), and they reflect
Gorodetskaya et al: Health-related quality of life and utility estimates in CKD 2807
the population of persons with CKD referred to an am-
bulatory nephrology practice, rather than all individuals
with CKD. We cannot exclude the possibility of significant
response bias. However, nonresponders were older, with
more comorbid disease, so that the measured values for
HRQOL and utility, while distressing, may be more fa-
vorable than what would be observed in the general CKD
population. We did not explore depression or cognitive
impairment, two conditions that are relatively common
in CKD and ESRD that might have influenced the results
[38, 39]. A large fraction of subjects were of Asian or Pa-
cific Islander ethnicity; since the MDRD equation has not
been validated in these groups, we may have misclassified
some subjects by eGFR category. A relatively large frac-
tion of subjects were lost to follow-up after the transition
to dialysis; more complete follow-up during this impor-
tant transition might have provided more power to detect
changes in addition to those described on the Burden and
Effects of kidney disease. Imprecision in determining the
change in kidney function using the change in eGFR (due
to changes in serum creatinine unrelated to kidney func-
tion, such as muscle wasting) may have also reduced the
power of the longitudinal analyses. Finally, loss to follow-
up may have biased the analyses, as subjects with lower
health and functional status are more likely to die, be hos-
pitalized, or otherwise refuse to participate in research.
CONCLUSION
HRQOL and utility are distressingly low in persons
with CKD. Elements of the KDQOL-36TM and HUI-3
can be used to evaluate the burden of kidney disease
and its effects on HRQOL, physical function, and util-
ity, and should be incorporated into CKD management
strategies. Self-reported outcomes should be considered
when evaluating health policy decisions that affect this
population.
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